POTASSIUM CHLORIDE INJECTION

Manufacturer
ICU Medical Inc. | Otsuka ICU Medical LLC
Effective date
2025-10-29
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
10
Source
monthly-update
Hydrated at
2026-07-17 21:40:52

Label at a glance#

ProductPotassium Chloride
Active ingredientPOTASSIUM CHLORIDE
Label structure19 sections

Boxed warning

Highly Concentrated

Indications and uses

Potassium Chloride Injection is indicated in the treatment of potassium deficiency states when oral replacement is not feasible. THIS HIGHLY CONCENTRATED, READY-TO-USE POTASSIUM CHLORIDE INJECTION IS INTENDED FOR THE MAINTENANCE OF SERUM K + LEVELS AND FOR POTASSIUM SUPPLEMENTATION IN FLUID RESTRICTED PATIENTS WHO CANNOT ACCOMMODATE ADDITIONAL VOLUMES OF FLUID ASSOCIATED WITH POTASSIUM SOLUTIONS OF LOWER CONCENTRA...

Dosage and administration

The dose and rate of administration are dependent upon the specific condition of each patient. Administer intravenously only with a calibrated infusion device at a slow, controlled rate. Because pain associated with peripheral infusion of Potassium Chloride solution has been reported, whenever possible, administration via central route is recommended for thorough dilution by the blood stream and avoidance of extra...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

For Use Only With A Calibrated Infusion Device

BOXED WARNING SECTION

Highly Concentrated

SPL UNCLASSIFIED SECTION

Flexible Plastic Container

Ready To Use

Rx only

DESCRIPTION

DESCRIPTION SECTION

This Potassium Chloride Injection is a sterile, nonpyrogenic, highly concentrated, ready-to-use solution of Potassium Chloride, USP in Water for Injection, USP for electrolyte replenishment in a single dose container for intravenous administration. It contains no antimicrobial agents.

Potassium

Chloride

Injection

mEq Potassium/

Container

Composition

(g/L)

Potassium

Chloride, USP

(KCl)

Osmolarity*

(mOsmol/L)

(calc)

pH

Ionic Concentration

(mEq/L)

Potassium

Chloride

10 mEq/100 mL

7.45

200

5.8

(4.0 to 8.0)

100

100

10 mEq/50 mL

20 mEq/100 mL

14.9

400

5.8

(4.0 to 8.0)

200

200

20 mEq/50 mL

40 mEq/100 mL

29.8

799

5.8

(4.0 to 8.0)

400

400

*Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions (≥600 mOsmol/L) may cause vein damage.

This flexible plastic container is fabricated from a specially formulated polyvinylchloride. Exposure to temperatures above 25°C (77°F) during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain of its chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Potassium is the major cation of body cells (160 mEq/liter of intracellular water) and is concerned with the maintenance of body fluid composition and electrolyte balance. Potassium participates in carbohydrate utilization, protein synthesis, and is critical in the regulation of nerve conduction and muscle contraction, particularly in the heart. Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base of the body are reflected by changes in the chloride concentration.

Normally about 80 to 90% of the potassium intake is excreted in the urine, the remainder in the stools and to a small extent, in the perspiration. The kidney does not conserve potassium well so that during fasting, or in patients on a potassium-free diet, potassium loss from the body continues resulting in potassium depletion. A deficiency of either potassium or chloride will lead to a deficit of the other.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Potassium Chloride Injection is indicated in the treatment of potassium deficiency states when oral replacement is not feasible.

THIS HIGHLY CONCENTRATED, READY-TO-USE POTASSIUM CHLORIDE INJECTION IS INTENDED FOR THE MAINTENANCE OF SERUM K + LEVELS AND FOR POTASSIUM SUPPLEMENTATION IN FLUID RESTRICTED PATIENTS WHO CANNOT ACCOMMODATE ADDITIONAL VOLUMES OF FLUID ASSOCIATED WITH POTASSIUM SOLUTIONS OF LOWER CONCENTRATION.

When using these products, these patients should be on continuous cardiac monitoring and frequent testing for serum potassium concentration and acid-base balance.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Potassium Chloride Injection is contraindicated in diseases where high potassium levels may be encountered, and in patients with hyperkalemia, renal failure and in conditions in which potassium retention is present.

WARNINGS

WARNINGS SECTION

THIS HIGHLY CONCENTRATED, READY-TO-USE POTASSIUM CHLORIDE INJECTION IS INTENDED FOR THE MAINTENANCE OF SERUM K + LEVELS AND FOR POTASSIUM SUPPLEMENTATION IN FLUID RESTRICTED PATIENTS WHO CANNOT ACCOMMODATE ADDITIONAL VOLUMES OF FLUID ASSOCIATED WITH POTASSIUM SOLUTIONS OF LOWER CONCENTRATION.

TO AVOID POTASSIUM INTOXICATION, DO NOT INFUSE THESE SOLUTIONS RAPIDLY.

PATIENTS REQUIRING HIGHLY CONCENTRATED SOLUTIONS SHOULD BE KEPT ON CONTINUOUS CARDIAC MONITORING AND UNDERGO FREQUENT TESTING FOR SERUM POTASSIUM AND ACID-BASE BALANCE, ESPECIALLY IF THEY RECEIVE DIGITALIS.

In patients with renal insufficiency, administration of potassium chloride may cause potassium intoxication and life-threatening hyperkalemia.

Administer intravenously only with a calibrated infusion device at a slow, controlled rate. (See DOSAGE AND ADMINISTRATION.) Because pain associated with peripheral infusion of Potassium Chloride solution has been reported, whenever possible administration via a central route is recommended for thorough dilution by the blood stream and avoidance of extravasation. Highest concentrations (300 and 400 mEq/L) should be exclusively administered via central route.

The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration.

PRECAUTIONS

PRECAUTIONS SECTION

INFORMATION FOR PATIENTS SECTION

Laboratory Tests

LABORATORY TESTS SECTION

Serum potassium levels are not necessarily indicative of tissue potassium levels. Solutions containing potassium should be used with caution in the presence of cardiac or renal disease.

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Significant deviations from normal concentrations may require the use of additional electrolyte supplements, or the use of electrolyte-free dextrose solutions to which individualized electrolyte supplements may be added.

DRUG INTERACTIONS SECTION

Pregnancy:

PREGNANCY SECTION

Pregnancy Category C. Animal reproduction studies have not been conducted with potassium chloride. It is also not known whether potassium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium chloride should be given to a pregnant woman only if clearly needed.

Pediatric Use:

PEDIATRIC USE SECTION

These products should not be used in pediatric patients at this time.

Do not administer unless solution is clear and seal is intact.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Potassium intoxication with mild or severe hyperkalemia has been reported. The signs and symptoms of intoxication include paresthesia of the extremities, areflexia, muscular or respiratory paralysis, mental confusion, weakness, hypotension, cardiac arrhythmia, heart block, electrographic abnormalities and cardiac arrest. EKG abnormalities serve as a clinical reflection of the seriousness of changes in serum potassium concentrations: peaked T waves and prolonged P-R intervals usually occur with modest elevations above the upper limit of normal potassium concentrations; P waves disappear, the QRS complex widens, and eventual asystole usually occurs with higher elevations.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

Infusion of highly concentrated potassium chloride solutions may cause local pain and vein irritation. (See WARNINGS).

Reactions reported with the use of potassium-containing solutions include nausea, vomiting, and abdominal pain and diarrhea.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

OVERDOSAGE

OVERDOSAGE SECTION

In the event of hyperkalemia, discontinue the infusion immediately and institute corrective therapy to reduce serum potassium levels as necessary. The use of potassium containing foods or medications must also be eliminated.

Treatment of mild to severe hyperkalemia with signs and symptoms of potassium intoxication includes the following:

  1. Dextrose Injection, USP, 10% or 25%, containing 10 units of crystalline insulin per 20 grams of dextrose administered intravenously, 300 to 500 mL per hour.

  2. Absorption and exchange of potassium using sodium or ammonium cycle cation exchange resin, orally and as retention enema.

  3. Hemodialysis and peritoneal dialysis.

In cases of digitalization, too rapid a lowering of plasma potassium concentration can cause digitalis toxicity.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The dose and rate of administration are dependent upon the specific condition of each patient.

Administer intravenously only with a calibrated infusion device at a slow, controlled rate. Because pain associated with peripheral infusion of Potassium Chloride solution has been reported, whenever possible, administration via central route is recommended for thorough dilution by the blood stream and avoidance of extravasation. Highest concentrations (300 and 400 mEq/L) should be exclusively administered via central route.

Recommended administration rates should not usually exceed 10 mEq/hour or 200 mEq for a 24-hour period if the serum potassium level is greater than 2.5 mEq/liter.

In urgent cases where the serum potassium level is less than 2 mEq/liter or where severe hypokalemia is a threat (serum potassium level less than 2 mEq/liter and electrocardiographic changes and/or muscle paralysis), rates up to 40 mEq/hour or 400 mEq over a 24-hour period can be administered very carefully when guided by continuous monitoring of the EKG and frequent serum K+ determinations to avoid hyperkalemia and cardiac arrest.

Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions where possible.

Do not add supplementary medication.

Preparation for Administration

(Use aseptic technique)

  1. Close flow control clamp of administration set.

  2. Remove cover from outlet port at bottom of container.

  3. Insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. NOTE: See full directions on administration set carton.

  4. Suspend container from hanger.

  5. Squeeze and release drip chamber to establish proper fluid level in chamber.

  6. Open flow control clamp and clear air from set. Close clamp.

  7. Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.

  8. Regulate rate of administration with flow control clamp.

WARNING: Do not use flexible container in series connections. Do not add supplementary medication. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.

HOW SUPPLIED

HOW SUPPLIED SECTION

Potassium Chloride Injection in flexible plastic containers is available as follows:

NDC No.

Potassium per container

0409–7074–26

10 mEq/100 mL

0990-7074-2610 mEq/100 mL

0409–7075–14

10 mEq/50 mL

0990-7075-1410 mEq/50 mL

0409–7075–26

20 mEq/100 mL

0990-7075-2620 mEq/100 mL

0409–7077–14

20 mEq/50 mL

0990-7077-1420 mEq/50 mL

0409–7077–26

40 mEq/100 mL

0990-7077-2640 mEq/100 mL

ICU Medical is transitioning NDC codes from "0409" to a "0990" labeler code. Both NDC codes are expected to be in the market for a period of time.

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

Revised: June, 2018

EN-4654

ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

PRINCIPAL DISPLAY PANEL - 100 mL Bag Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

For Use Only With A Calibrated Infusion Device

Highly Concentrated
100 mEq/L

100 mL
NDC 0990-7074-26

POTASSIUM CHLORIDE Inj.

10
mEq

EACH 100 mL CONTAINS POTASSIUM CHLORIDE
745 mg IN WATER FOR INJECTION. ELECTROLYTES
PER 1000 mL: POTASSIUM 100 mEq; CHLORIDE
100 mEq.
200 mOsmol/LITER (CALC.)
pH 5.8 (4.0 to 8.0)

DO NOT ADD SUPPLEMENTARY MEDICATION.
WHENEVER POSSIBLE USE CENTRAL ROUTE.

SINGLE-DOSE CONTAINER. FOR I.V. USE. USUAL
DOSAGE: SEE INSERT. STERILE, NONPYROGENIC.
USE ONLY IF SOLUTION IS CLEAR AND CONTAINER
IS UNDAMAGED. MUST NOT BE USED IN SERIES
CONNECTIONS.

Rx ONLY

3
V
CONTAINS DEHP

ICU Medical, Inc.,
Lake Forest, Illinois, 60045, USA

icumedical

IM-4339

PRINCIPAL DISPLAY PANEL - 100 mL Bag Label
PRINCIPAL DISPLAY PANEL - 100 mL Bag Label

PRINCIPAL DISPLAY PANEL - 100 mL Bag Pouch Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

TO OPEN – TEAR AT NOTCH
NDC 0990-7074-26
For use only with a calibrated infusion device.
HIGHLY CONCENTRATED

100
mEq/L

POTASSIUM
CHLORIDE Inj.

10
mEq

Total in 100 mL

Each 100 mL contains potassium chloride 745 mg in water for injection.
Electrolytes per 1000 mL: potassium 100 mEq; chloride 100 mEq.
200 mOsmol/liter (CALC.)
pH 5.8 (4.0 to 8.0)

DO NOT ADD SUPPLEMENTARY MEDICATION. WHENEVER POSSIBLE USE
CENTRAL ROUTE.

Single-dose container. For I.V. use. Usual dosage: See insert. Sterile, nonpyrogenic.
Use only if solution is clear. After removing the overwrap, check for minute leaks
by squeezing container firmly. If leaks are found, discard unit as sterility may be
impaired. Must not be used in series connections.

The overwrap is a moisture barrier. Do not remove unit from overwrap until ready
for use. Use unit promptly when pouch is opened. Store at 20 to 25°C (68 to 77°F). [See
USP Controlled Room Temperature.] Protect from freezing. See insert.

Rx only

7
OTHER

F WR-0529

ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

icumedical

PRINCIPAL DISPLAY PANEL - 100 mL Bag Pouch Label
PRINCIPAL DISPLAY PANEL - 100 mL Bag Pouch Label

PRINCIPAL DISPLAY PANEL - 50 mL Bag Label - IM-4340

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

For Use Only With A Calibrated Infusion Device

Highly Concentrated
200 mEq/L

50 mL
NDC 0990-7075-14

POTASSIUM CHLORIDE Inj.

10
mEq

EACH 100 mL CONTAINS POTASSIUM CHLORIDE
1490 mg IN WATER FOR INJECTION. ELECTROLYTES
PER 1000 mL: POTASSIUM 200 mEq; CHLORIDE
200 mEq.
400 mOsmol/LITER (CALC.)
pH 5.8 (4.0 to 8.0)

DO NOT ADD SUPPLEMENTARY MEDICATION.
WHENEVER POSSIBLE USE CENTRAL ROUTE.

SINGLE-DOSE CONTAINER. USUAL DOSAGE: SEE
INSERT. FOR I.V. USE. STERILE, NONPYROGENIC.
USE ONLY IF SOLUTION IS CLEAR AND CONTAINER
IS UNDAMAGED. MUST NOT BE USED IN SERIES
CONNECTIONS.

Rx ONLY

3
V
CONTAINS DEHP

icumedical

IM-4340

ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

PRINCIPAL DISPLAY PANEL - 50 mL Bag Label - IM-4340
PRINCIPAL DISPLAY PANEL - 50 mL Bag Label - IM-4340

PRINCIPAL DISPLAY PANEL - 50 mL Bag Pouch Label - WR-0530

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

TO OPEN – TEAR AT NOTCH
NDC 0990-7075-14
For use only with a calibrated infusion device.
HIGHLY CONCENTRATED

200
mEq/L

POTASSIUM
CHLORIDE Inj.

10
mEq

Total in 50 mL

Each 100 mL contains potassium chloride 1490 mg in water for injection.
Electrolytes per 1000 mL: potassium 200 mEq; chloride 200 mEq.
400 mOsmol/liter (CALC.)
pH 5.8 (4.0 to 8.0)

DO NOT ADD SUPPLEMENTARY MEDICATION. WHENEVER POSSIBLE USE
CENTRAL ROUTE.

Single-dose container. For I.V. use. Usual dosage: See insert. Sterile, nonpyrogenic.
Use only if solution is clear. After removing the overwrap, check for minute leaks
by squeezing container firmly. If leaks are found, discard unit as sterility may be
impaired. Must not be used in series connections.

The overwrap is a moisture barrier. Do not remove unit from overwrap until ready
for use. Use unit promptly when pouch is opened. Store at 20 to 25°C (68 to 77°F).
[See USP Controlled Room Temperature.] Protect from freezing. See insert.

Rx only

7
OTHER

F WR-0530

ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

icumedical

PRINCIPAL DISPLAY PANEL - 50 mL Bag Pouch Label - WR-0530
PRINCIPAL DISPLAY PANEL - 50 mL Bag Pouch Label - WR-0530

PRINCIPAL DISPLAY PANEL - 50 mL Bag Label - IM-4342

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

For Use Only With A Calibrated Infusion Device

Highly Concentrated
400 mEq/L

50 mL
NDC 0990-7077-14

POTASSIUM CHLORIDE Inj.

20
mEq

EACH 50 mL CONTAINS POTASSIUM CHLORIDE
1.49 g IN WATER FOR INJECTION. ELECTROLYTES
PER 1000 mL: POTASSIUM 400 mEq; CHLORIDE
400 mEq.
799 mOsmol/LITER (CALC.)
pH 5.8 (4.0 to 8.0)
HYPERTONIC – MAY CAUSE VEIN DAMAGE.
DO NOT ADD SUPPLEMENTARY MEDICATION.
WHENEVER POSSIBLE USE CENTRAL ROUTE.
DISCONTINUE INFUSION IF ADVERSE REACTION
OCCURS. SINGLE-DOSE CONTAINER. FOR I.V.
USE. USUAL DOSAGE: SEE INSERT. STERILE,
NONPYROGENIC. USE ONLY IF SOLUTION IS CLEAR
AND CONTAINER IS UNDAMAGED. MUST NOT BE
USED IN SERIES CONNECTIONS.

Rx ONLY

3
V
CONTAINS DEHP

ICU Medical, Inc.,
Lake Forest, Illinois, 60045, USA

IM-4342

icumedical

PRINCIPAL DISPLAY PANEL - 50 mL Bag Label - IM-4342
PRINCIPAL DISPLAY PANEL - 50 mL Bag Label - IM-4342

PRINCIPAL DISPLAY PANEL - 50 mL Bag Pouch Label - WR-0536

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

TO OPEN – TEAR AT NOTCH
NDC 0990-7077-14
For use only with a calibrated infusion device.
HIGHLY CONCENTRATED

20
mEq

POTASSIUM
CHLORIDE Inj.

400
mEq/L

Total in 50 mL

Each 50 mL contains potassium chloride 1.49 g in water for injection. Electrolytes
per 1000 mL: potassium 400 mEq; chloride 400 mEq.
799 mOsmol/liter (CALC.)
pH 5.8 (4.0 to 8.0)
Hypertonic – may cause vein damage.

DO NOT ADD SUPPLEMENTARY MEDICATION. WHENEVER POSSIBLE USE
CENTRAL ROUTE.

Discontinue infusion if adverse reaction occurs.

Single-dose container. For I.V. use. Usual dosage: See insert. Sterile, nonpyrogenic.
Use only if solution is clear. After removing the overwrap, check for minute leaks by
squeezing container firmly. If leaks are found, discard unit as sterility may be impaired.
Must not be used in series connections.

The overwrap is a moisture barrier. Do not remove unit from overwrap until ready
for use. Use unit promptly when pouch is opened. Store at 20 to 25°C (68 to 77°F).
[See USP Controlled Room Temperature.] Protect from freezing. See insert.

Rx only

7
OTHER

F WR-0536

ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

icumedical

PRINCIPAL DISPLAY PANEL - 50 mL Bag Pouch Label - WR-0536
PRINCIPAL DISPLAY PANEL - 50 mL Bag Pouch Label - WR-0536

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
9e37788c-b1bf-42ae-aac9-b60601606144Product name820260122
95250459-30e4-45c1-b08a-993044f49109Product name220250805
d9771140-739b-484b-ae64-b79528ff1211Product name320250801
efd58dcf-540a-4531-8766-e713129ca6f2Product name120250307
30b0ac6e-02aa-0e5c-0d8b-cffdf3a282b2Product name520250304
1527ac37-808d-43be-a63e-74e1258dbe46Product name920250219
bed0530e-f939-4541-956b-6928a2f6404fProduct name120241008
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name620240814
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
9fcb7a91-de07-4f00-aabf-e4d6fda403d5Product name820230322
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
0ec3537a-6c9b-432a-896c-b9ea8723049aProduct name920200701
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
7916de40-e296-41f0-b811-6d0df1a33e2cProduct name920180627
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name220171212
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
26acd337-b838-40ac-bcbc-05c3b81c8712Product name120170323
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0990-7074-26ML - Milliliter0990-70745e40c8c2-68d7-4fe1-a2f3-fa210d7f8b3212019-09-05
0990-7075-14ML - Milliliter0990-7075ad03dfa0-8df5-4785-821d-068ac0f17dee12019-12-10
0990-7075-26ML - Milliliter0990-7075d850890b-21d8-45e1-910c-e737ce84160112019-08-06
0990-7077-14ML - Milliliter0990-707765707846-c96b-4ff1-8491-fcb0f650dd1c12019-12-10
0990-7077-26ML - Milliliter0990-7077e9abc608-b19a-4486-8b52-7954ac88e79312020-05-08

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML · Source PDF

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
92025-10-29full-release2026-05-31 22:03:46
82020-06-18full-release2026-05-31 21:16:48

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 6 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N020161-001POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINERPOTASSIUM CHLORIDE745MG/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30
N020161-002POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINERPOTASSIUM CHLORIDE1.49GM/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30
N020161-003POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINERPOTASSIUM CHLORIDE2.24GM/100MLINJECTABLE / INJECTIONRLD1998-08-11
N020161-004POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINERPOTASSIUM CHLORIDE2.98GM/100MLINJECTABLE / INJECTIONAPRLD, RS1998-08-11
N020161-005POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINERPOTASSIUM CHLORIDE14.9MG/MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30
N020161-006POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINERPOTASSIUM CHLORIDE29.8MG/MLINJECTABLE / INJECTIONAPRLD, RS1998-08-11

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 5 matching rows.

Application-product, TE code table
Application-productTE code
N020161-001AP
N020161-002AP
N020161-004AP
N020161-005AP
N020161-006AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 7 · 270 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N020161-001POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER745MG/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30d4dbc9d85df4…
2026-11-14 07:37:172026-10N020161-002POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER1.49GM/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30d4dbc9d85df4…
2026-11-14 07:37:172026-10N020161-003POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER2.24GM/100MLINJECTABLE / INJECTIONRLD1998-08-11d4dbc9d85df4…
2026-11-14 07:37:172026-10N020161-004POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER2.98GM/100MLINJECTABLE / INJECTIONAPRLD, RS1998-08-11d4dbc9d85df4…
2026-11-14 07:37:172026-10N020161-005POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER14.9MG/MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30d4dbc9d85df4…
2026-11-14 07:37:172026-10N020161-006POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER29.8MG/MLINJECTABLE / INJECTIONAPRLD, RS1998-08-11d4dbc9d85df4…
2026-10-15 13:18:302026-09N020161-001POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER745MG/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30c2088c7a36db…
2026-10-15 13:18:302026-09N020161-002POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER1.49GM/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30c2088c7a36db…
2026-10-15 13:18:302026-09N020161-003POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER2.24GM/100MLINJECTABLE / INJECTIONRLD1998-08-11c2088c7a36db…
2026-10-15 13:18:302026-09N020161-004POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER2.98GM/100MLINJECTABLE / INJECTIONAPRLD, RS1998-08-11c2088c7a36db…
2026-10-15 13:18:302026-09N020161-005POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER14.9MG/MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30c2088c7a36db…
2026-10-15 13:18:302026-09N020161-006POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER29.8MG/MLINJECTABLE / INJECTIONAPRLD, RS1998-08-11c2088c7a36db…
2026-09-14 22:38:342026-08N020161-001POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER745MG/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-3084e616aacf4f…
2026-09-14 22:38:342026-08N020161-002POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER1.49GM/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-3084e616aacf4f…
2026-09-14 22:38:342026-08N020161-003POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER2.24GM/100MLINJECTABLE / INJECTIONRLD1998-08-1184e616aacf4f…
2026-09-14 22:38:342026-08N020161-004POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER2.98GM/100MLINJECTABLE / INJECTIONAPRLD, RS1998-08-1184e616aacf4f…
2026-09-14 22:38:342026-08N020161-005POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER14.9MG/MLINJECTABLE / INJECTIONAPRLD, RS1992-11-3084e616aacf4f…
2026-09-14 22:38:342026-08N020161-006POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER29.8MG/MLINJECTABLE / INJECTIONAPRLD, RS1998-08-1184e616aacf4f…
2026-08-18 06:07:402026-07N020161-001POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER745MG/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30caaa826d4ba7…
2026-08-18 06:07:402026-07N020161-002POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER1.49GM/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30caaa826d4ba7…
2026-08-18 06:07:402026-07N020161-003POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER2.24GM/100MLINJECTABLE / INJECTIONRLD1998-08-11caaa826d4ba7…
2026-08-18 06:07:402026-07N020161-004POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER2.98GM/100MLINJECTABLE / INJECTIONAPRLD, RS1998-08-11caaa826d4ba7…
2026-08-18 06:07:402026-07N020161-005POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER14.9MG/MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30caaa826d4ba7…
2026-08-18 06:07:402026-07N020161-006POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER29.8MG/MLINJECTABLE / INJECTIONAPRLD, RS1998-08-11caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N020161-001POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER745MG/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020161-002POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER1.49GM/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020161-003POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER2.24GM/100MLINJECTABLE / INJECTIONRLD1998-08-11011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020161-004POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER2.98GM/100MLINJECTABLE / INJECTIONAPRLD, RS1998-08-11011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020161-005POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER14.9MG/MLINJECTABLE / INJECTIONAPRLD, RS1992-11-30011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020161-006POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER29.8MG/MLINJECTABLE / INJECTIONAPRLD, RS1998-08-11011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020161-001POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER745MG/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-3031067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020161-002POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER1.49GM/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-3031067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020161-003POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER2.24GM/100MLINJECTABLE / INJECTIONRLD1998-08-1131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020161-004POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER2.98GM/100MLINJECTABLE / INJECTIONAPRLD, RS1998-08-1131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020161-005POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER14.9MG/MLINJECTABLE / INJECTIONAPRLD, RS1992-11-3031067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020161-006POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER29.8MG/MLINJECTABLE / INJECTIONAPRLD, RS1998-08-1131067a03dcf5…
2025-08-23 18:47 UTC2025-08N020161-001POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER745MG/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-306a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020161-002POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER1.49GM/100MLINJECTABLE / INJECTIONAPRLD, RS1992-11-306a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020161-003POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER2.24GM/100MLINJECTABLE / INJECTIONRLD1998-08-116a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020161-004POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER2.98GM/100MLINJECTABLE / INJECTIONAPRLD, RS1998-08-116a471c1ec25d…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 6 · 225 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10N020161-001AP1d4dbc9d85df4…
2026-11-14 07:37:172026-10N020161-002AP1d4dbc9d85df4…
2026-11-14 07:37:172026-10N020161-004AP1d4dbc9d85df4…
2026-11-14 07:37:172026-10N020161-005AP1d4dbc9d85df4…
2026-11-14 07:37:172026-10N020161-006AP1d4dbc9d85df4…
2026-10-15 13:18:302026-09N020161-001AP1c2088c7a36db…
2026-10-15 13:18:302026-09N020161-002AP1c2088c7a36db…
2026-10-15 13:18:302026-09N020161-004AP1c2088c7a36db…
2026-10-15 13:18:302026-09N020161-005AP1c2088c7a36db…
2026-10-15 13:18:302026-09N020161-006AP1c2088c7a36db…
2026-09-14 22:38:342026-08N020161-001AP184e616aacf4f…
2026-09-14 22:38:342026-08N020161-002AP184e616aacf4f…
2026-09-14 22:38:342026-08N020161-004AP184e616aacf4f…
2026-09-14 22:38:342026-08N020161-005AP184e616aacf4f…
2026-09-14 22:38:342026-08N020161-006AP184e616aacf4f…
2026-08-18 06:07:402026-07N020161-001AP1caaa826d4ba7…
2026-08-18 06:07:402026-07N020161-002AP1caaa826d4ba7…
2026-08-18 06:07:402026-07N020161-004AP1caaa826d4ba7…
2026-08-18 06:07:402026-07N020161-005AP1caaa826d4ba7…
2026-08-18 06:07:402026-07N020161-006AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N020161-001AP1011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020161-002AP1011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020161-004AP1011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020161-005AP1011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020161-006AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020161-001AP131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020161-002AP131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020161-004AP131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020161-005AP131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020161-006AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08N020161-001AP16a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020161-002AP16a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020161-004AP16a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020161-005AP16a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020161-006AP16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020161-001AP1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020161-002AP1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020161-004AP1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020161-005AP1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020161-006AP1fd3edfee7708…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Potassium ChloridePOTASSIUM CHLORIDEICU Medical Inc.eb56a807-ea94-4edb-9811-a04b195684682025-10-29Boxed warning, Warnings, Adverse reactionsExact identifier
ndc (package): 0990-7077-26
ndc (package): 0990-7075-26
ndc (package): 0990-7075-14
ndc (package): 0990-7077-14
ndc (package): 0990-7074-26
ndc (product): 0990-7074
ndc (product): 0990-7075
ndc (product): 0990-7077
ndc11 (package): 00990707714
ndc11 (package): 00990707526
ndc11 (package): 00990707726
ndc11 (package): 00990707514
ndc11 (package): 00990707426
spl id: e76c9e23-41f3-4d57-a5bf-684417a53e5e
spl set id: eb56a807-ea94-4edb-9811-a04b19568468

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.